The Competition Commission of India (CCI) has approved the formation of a joint venture (JV) for consumer healthcare products by pharmaceutical giants Glaxosmithkline (GSK) and Pfizer. In December 2018, GSK had reached an agreement with Pfizer to combine their consumer health businesses into a new JV with combined sales of around $12.7 billion (around Rs 88,900 crore).
The proposed combination involves acquisition of Pfizer's consumer healthcare business by GSK, and the combination of GSK and Pfizer consumer healthcare business into a global consumer healthcare joint venture under the sole control of GSK. After the deal, GSK will have a majority controlling equity interest of 68 percent in the combined consumer healthcare business, while Pfizer will have a minority non-controlling equity interest of the remaining 32 percent.
Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: